Skip to content
Two pipettes with red and yellow liquid

Approved treatments for inherited EB

EB Resnet provides an overview of the approved treatment options for EB.

Please note that some therapies have only been approved in the USA or in the EU. The overview is primarily intended to give an overview of approved treatments worldwide.


There are other drugs and therapies being evaluated in clinical trials. Please have a look on the Clinical Trials Database to inform yourself about ongoing trials.

Current overview

Filsuvez Logo

Filsuvez®

Filsuvez®, developed by Chiesi (former Amryt) is a topical gel for the treatment of partial thickness wounds related to dystrophic (DEB) and junctional Epidermolysis Bullosa (JEB). Approved by: EMA (2022) & FDA (2023)

Learn more about Filsuvez® Gel
Vyjuvek Logo

VYJUVEK®

VYJUVEK® (beremagene geperpavec-svdt) (VYEJOO-VEK), developed by Krystal Biotech, is the first approved treatment to address the genetic cause of dystrophic Epidermolysis Bullosa (DEB). Approved by: FDA (2023)

Learn more about VYJUVEK® Gel

Clinical translation

EB Clinical trials database

Search and find out more about current and completed EB clinical trials.

To the database
Girl laughs at her mother and a doctor

Clinical trials & patient access

Knowing the patients' needs and possibilities is crucial to push translational research.

How to access patients
Researcher places a sample on a shelf in the laboratory

Current Therapeutic Approaches

Find out more about current therapeutic approaches for EB therapy development.

Current Approaches
Back to main navigation